Primer Amiloidozun Nadir Bir Karaciğer Tutulumu: Budd-Chiari Sendromu

Kaynakça (8)

1. Aydinli M, Bayraktar Y. Budd-Chiari syndrome: etiology, pathogenesis and diagnosis. World J Gastroenterol 2007;13:2693-2696
2. Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587- 591
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59
4. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-683
5. Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, Merlini G. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. Amyloid 1999;6:273-277
6. Cançado GGL, Faria LC, Osório FMF, Vidigal PVT, Couto CA, Ferrari TCA. Budd Chiari syndrome associated with AL amyloidosis: a coagulation paradox. Amyloid 2018;25:70-71
7. Guo HF, Su HL, Mao JJ, Sun C, Wang J, Zhou X. Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma. Int J Clin Pharmacol Ther 2010;48:776-778
8. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 2011;11:228-236.